Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
Abstract Importance Widely available and affordable options for the outpatient management of COVID-19 are needed, particularly therapies that prevent hospitalization.Objective Perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of COVID-19.Data Sources World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov.Study Selection Completed outpatient trials with available results which compared fluvoxamine to placebo.Data Extraction and Synthesis We followed the PRISMA 2020 guidelines. We extracted study details in terms of inclusion criteria, trial demographics and the pre-specified outcome of all-cause hospitalization. Risk of bias was assessed by the Cochrane Risk of Bias 2 tool. We conducted a frequentist random effects meta-analysis, as well as two sensitivity analyses using a Bayesian random effects meta-analysis with different estimates of prior probability: a weakly neutral prior (50% chance of efficacy with 95% confidence interval for Risk Ratio [RR] between 0.5 and 2) and a moderately optimistic prior (85% chance of efficacy). We contextualized the results by estimating the probability of any effect (RR ≤1) and moderate effect (RR ≤0.9) on reducing hospitalization.Main Outcome(s) and Measure(s) All cause hospitalization.Results 2196 participants were included from 3 identified trials. The risk ratios for hospitalization were 0.75 (95%CI, 0.57-0.97) for the frequentist analysis, 0.78 (95%CI 0.58-1.08) for the Bayesian weakly neutral prior, and 0.73 (95%CI, 0.53-1.01) for the Bayesian moderately optimistic prior. Depending on the scenario, the probability of any effect on hospitalization ranged from 94.1% to 98.3% and a moderate effect from 81.6% to 91.1%.Conclusions and Relevance Under a variety of assumptions, fluvoxamine shows a high probability of preventing hospitalization in outpatients with COVID-19. While ongoing randomized trials are important to evaluate alternative doses, explore the effectiveness in vaccinated patients, and provide further refinement to these estimates, fluvoxamine could be recommended as a treatment option, particularly in resource-limited settings or persons without access to SARS-CoV-2 monoclonal antibody therapy or direct antivirals.Key Points Question Does early administration of fluvoxamine prevent hospitalization in symptomatic adult outpatients with confirmed COVID-19?Findings In this meta-analysis with Bayesian sensitivity analyses that accounted for varying prior probabilities, there was a high probability (94.1% to 98.3%) that fluvoxamine reduces hospitalization with frequentist risk ratio of 0.75 (95%CI 0.57-0.97).Meaning Fluvoxamine is a widely available and inexpensive option that prevents hospitalization in patients with early COVID-19 based on randomized controlled trial evidence to date..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 23. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Todd C. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.12.17.21268008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI033269033 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI033269033 | ||
| 003 | DE-627 | ||
| 005 | 20230429090039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211222s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.17.21268008 |2 doi | |
| 035 | |a (DE-627)XBI033269033 | ||
| 035 | |a (biorXiv)10.1101/2021.12.17.21268008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Lee, Todd C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Importance Widely available and affordable options for the outpatient management of COVID-19 are needed, particularly therapies that prevent hospitalization.Objective Perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of COVID-19.Data Sources World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov.Study Selection Completed outpatient trials with available results which compared fluvoxamine to placebo.Data Extraction and Synthesis We followed the PRISMA 2020 guidelines. We extracted study details in terms of inclusion criteria, trial demographics and the pre-specified outcome of all-cause hospitalization. Risk of bias was assessed by the Cochrane Risk of Bias 2 tool. We conducted a frequentist random effects meta-analysis, as well as two sensitivity analyses using a Bayesian random effects meta-analysis with different estimates of prior probability: a weakly neutral prior (50% chance of efficacy with 95% confidence interval for Risk Ratio [RR] between 0.5 and 2) and a moderately optimistic prior (85% chance of efficacy). We contextualized the results by estimating the probability of any effect (RR ≤1) and moderate effect (RR ≤0.9) on reducing hospitalization.Main Outcome(s) and Measure(s) All cause hospitalization.Results 2196 participants were included from 3 identified trials. The risk ratios for hospitalization were 0.75 (95%CI, 0.57-0.97) for the frequentist analysis, 0.78 (95%CI 0.58-1.08) for the Bayesian weakly neutral prior, and 0.73 (95%CI, 0.53-1.01) for the Bayesian moderately optimistic prior. Depending on the scenario, the probability of any effect on hospitalization ranged from 94.1% to 98.3% and a moderate effect from 81.6% to 91.1%.Conclusions and Relevance Under a variety of assumptions, fluvoxamine shows a high probability of preventing hospitalization in outpatients with COVID-19. While ongoing randomized trials are important to evaluate alternative doses, explore the effectiveness in vaccinated patients, and provide further refinement to these estimates, fluvoxamine could be recommended as a treatment option, particularly in resource-limited settings or persons without access to SARS-CoV-2 monoclonal antibody therapy or direct antivirals.Key Points Question Does early administration of fluvoxamine prevent hospitalization in symptomatic adult outpatients with confirmed COVID-19?Findings In this meta-analysis with Bayesian sensitivity analyses that accounted for varying prior probabilities, there was a high probability (94.1% to 98.3%) that fluvoxamine reduces hospitalization with frequentist risk ratio of 0.75 (95%CI 0.57-0.97).Meaning Fluvoxamine is a widely available and inexpensive option that prevents hospitalization in patients with early COVID-19 based on randomized controlled trial evidence to date. | ||
| 700 | 1 | |a Vigod, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Bortolussi-Courval, Émilie |e verfasserin |4 aut | |
| 700 | 1 | |a Hanula, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Boulware, David R. |e verfasserin |4 aut | |
| 700 | 1 | |a Lenze, Eric J. |e verfasserin |4 aut | |
| 700 | 1 | |a Reiersen, Angela M. |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, Emily G. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 23. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:23 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.17.21268008 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 23 |c 12 | ||
| 953 | |2 045F |a 570 | ||